CTNNB1 and neoplasm: The pronounced somatic mutations were also observed in patients in C2, including TP53, CTNNB1, TNN, and CACNA1E. Previous studies had revealed that the mutation of TP53 and CTNNB1 mediated cell cycle and WNT signaling pathways, resulting in tumor progression (33).